Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Chatzi L, Torrent M, Romieu I, Garcia-Esteban R, Ferrer C, Vioque J, Kogevinas M, Sunyer J. Diet, wheeze, and atopy in school children in Menorca, Spain. Pediatr Allergy Immunol. 2007 Sep;18(6):480-5. doi: 10.1111/j.1399-3038.2007.00596.x
Scrams DJ, McLeod LD. An expected response function approach to graphical differential item functioning. J Educ Meas. 2000 Jan 1;37(3):263-77.
Williams VSL, Rosa KR, McLeod L, Thissen D, Sanford EE. Projecting to the NAEP Scale: results from the North Carolina End‐of‐Grade Testing Program. J Educ Meas. 1998 Dec;35(4):277-96. doi: 10.1111/j.1745-3984.1998.tb00539.x
Williams VSL, Pommerich M, Thissen D. A comparison of developmental scales based on Thurstone methods and item response theory. J Educ Meas. 1998 Jun;35(2):93-107.